Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

Truist Financial analyst Joon Lee reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Truist Financial analyst Joon Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s shares closed ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

This page features the latest news about the Verona Pharma ADR stock. Piper Sandler lifts Verona Pharma shares target citing high COPD drug approval odds On Tuesday, Piper Sandler exhibited confidence ...

Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

Sanofi S.A. Part Cert-1.97% €8.03M ...